



June 16, 2022

Dear Healthcare Professional,

We are reaching out to give you an update on our Sturgis, MI plant and availability of metabolic products. On Monday evening, severe thunderstorms and heavy rains came through southwestern Michigan, resulting in high winds, hail, power outages and flood damage throughout the area. These torrential storms produced significant rainfall in a short period of time – overwhelming the city's stormwater system in Sturgis, Michigan and resulting in flooding in parts of the city, including areas of our plant.

As a result, Abbott has stopped production of its EleCare specialty formula that was underway to assess damage caused by the storm and clean and re-sanitize the plant. We have informed FDA and will conduct comprehensive testing in conjunction with the independent third party to ensure the plant is safe to resume production. This will likely delay production and distribution of new product for a few weeks.

Once the plant is re-sanitized and production resumes, we will again begin EleCare production, followed immediately by metabolic formulas.

As you may recall, on April 29, Abbott communicated that metabolic formula products previously on hold—and not part of the recall—would be released free of charge to patients in coordination with healthcare professionals based on need and on a case-by-case basis. These products met all testing and release requirements. Additionally, we've conducted enhanced microbiological testing to provide additional reassurance the products are safe.

Based on past orders reflecting historical demand of each metabolic product, including Similac PM 60/40, Abbott currently has ample supply of most metabolic products. This supply is sufficient to bridge historical demand until new metabolic products are produced and released. Abbott will continue to provide the current supply of metabolic products free of charge in coordination with healthcare professionals based on need and on a case-by-case basis.

Three metabolic formulas, ProViMin, Calcilo XD and Propimex-1, have lower inventories available. If historical demand for these products is considered this may not bridge all patients until new product is available. However, based on the current number of people accessing these products through the current process, there would be sufficient supply. Because we know that could change, we are advising healthcare professionals to conserve these products or use alternatives until new product is available.

Abbott will continue to work with healthcare professionals to fulfill requests for patients on a case-by-case basis based on need.

We appreciate your patience with us during this challenging time. Moving forward, we will provide you status updates.

For urgent patient needs or concerns, please contact the Abbott Metabolic Hotline at 1-800-986-8755.

Thank you,

Kanyn L. Wuy, MD, MPH

Karyn Wulf, MD, MPH Medical Director, Pediatrics

Courtney Allgeier, MS, RD, LD Research Scientist

On behalf of the Abbott Metabolic Team